lenalidomide viatris
viatris limited - lenalidomide 5mg - capsule - 5 mg - active: lenalidomide 5mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.
lenalidomide viatris
viatris limited - lenalidomide 7.5mg - capsule - 7.5 mg - active: lenalidomide 7.5mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin iron oxide black iron oxide yellow microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.
valsartan viatris 160 mg film-coated tablets
viatris limited - valsartan - film-coated tablet - angiotensin ii antagonists, plain; valsartan
valsartan viatris 320 mg film-coated tablets
viatris limited - valsartan - film-coated tablet - angiotensin ii antagonists, plain; valsartan
valsartan viatris 40 mg film-coated tablets
viatris limited - valsartan - film-coated tablet - angiotensin ii antagonists, plain; valsartan
valsartan viatris 80 mg film-coated tablets
viatris limited - valsartan - film-coated tablet - angiotensin ii antagonists, plain; valsartan
zoledronic acid viatris
viatris limited - zoledronic acid monohydrate 0.8528 mg/ml equivalent to zoledronic acid 0.8 mg/ml; - concentrate for infusion - 4 mg/5ml - active: zoledronic acid monohydrate 0.8528 mg/ml equivalent to zoledronic acid 0.8 mg/ml excipient: hydrochloric acid sodium citrate sodium hydroxide water for injection - · treatment of tumour-induced hypercalcaemia.
bisoprolol viatris
viatris limited - bisoprolol fumarate 10mg - film coated tablet - 10 mg - active: bisoprolol fumarate 10mg excipient: colloidal silicon dioxide croscarmellose sodium stear-o-wet m or ligamed mf bls-mb (magnesium stearate/sodium lauryl sulphate (94/6)) iron oxide red lactose microcrystalline cellulose opadry orange 40c83047 - treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.
bisoprolol viatris
viatris limited - bisoprolol fumarate 2.5mg - film coated tablet - 2.5 mg - active: bisoprolol fumarate 2.5mg excipient: colloidal silicon dioxide croscarmellose sodium stear-o-wet m or ligamed mf bls-mb (magnesium stearate/sodium lauryl sulphate (94/6)) iron oxide red iron oxide yellow lactose microcrystalline cellulose opadry grey 40c57557 - treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.
bisoprolol viatris
viatris limited - bisoprolol fumarate 5mg - film coated tablet - 5 mg - active: bisoprolol fumarate 5mg excipient: colloidal silicon dioxide croscarmellose sodium stear-o-wet m or ligamed mf bls-mb (magnesium stearate/sodium lauryl sulphate (94/6)) iron oxide yellow lactose microcrystalline cellulose opadry yellow 40c82321 - treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.